Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Bio-Rad Labs (BIO) PT Lowered to $400 at Citi
February 14, 2025 9:19 AM ESTCiti analyst Patrick Donnelly lowered the price target on Bio-Rad Labs (NYSE: BIO) to $400.00 (from $450.00) while maintaining a Buy rating.
The analyst comments "BIO guided core FY25 to grow +1.5-3.5% vs. consensus of +2.5%, with Life Sci at +1.5-3.5% vs. Dx at +2-3%. GM /... More
